January 2026 Research Update

This month added several small but patient-relevant signals about treatment in harder-to-treat Langerhans cell histiocytosis (LCH) situations, with the clearest data in adults with lung involvement. A small clinical trial in pulmonary LCH reported that many participants had improved breathing test results by 6 months, and symptom scores improved in the same time frame. Other reports in pulmonary hypertension linked to pulmonary LCH and in relapse/refractory childhood LCH suggest potential benefit from specific drug approaches, but those findings are based on very small, non-randomized experiences and need confirmation. [1] [2] [3]

For adults with pulmonary LCH, cladribine (a chemotherapy drug) was studied in 10 people with symptoms and airflow limitation or recent decline in lung function. At 6 months, 70% met the study's definition of lung function response, and 5 people were still responders at 12 months, alongside a reported median improvement in breathing-related quality of life scores. The report also noted one death before the 12-month visit and reported that no malignancies were detected in follow-up. [1]

In a small case series of pulmonary hypertension associated with pulmonary LCH, adding sotatercept to background triple therapy was followed by large improvements in walking distance and heart-lung pressure measurements in 3 people. Side effects were reported, including low platelets and bleeding symptoms, and one person stopped sotatercept after 14 months due to thrombocytopenia and bleeding. The authors also summarized previously published cases, underscoring that management has varied widely and that stronger studies are still needed. [2]

For children with recurrent or refractory LCH, a retrospective comparison of second-line regimens described high overall survival in the reported groups, with different patterns of blood count and liver-related side effects depending on the regimen. The strongest blood-related toxicity was reported with cladribine plus cytarabine in the subgroup with risk-organ involvement, while other regimens showed milder reported blood-related toxicity in this dataset. Because treatment assignment was not randomized and groups were small, this study mainly helps map what was tried and what toxicities were seen in routine care. [3]

For patients, the main new information this month is that lung-involved LCH continues to be an active treatment research area, with early evidence that some people may see measurable breathing improvements after cladribine in a small trial. For the more specialized situation of pulmonary hypertension related to pulmonary LCH, sotatercept was reported to coincide with major improvements in a few individuals, but this is still early, off-label experience with important side effects reported. For children whose LCH comes back or does not respond, this month adds a clearer picture of commonly used second-line combinations and their different toxicity profiles, but it does not establish which approach is best. These findings may matter now mainly as context for discussions and future research, and they remain uncertain until confirmed in larger, comparative studies. [1] [2] [3]

Across several pediatric studies this month, the picture that became clearer is that many children with LCH do well long-term, while a smaller subset faces relapse or later complications that affect daily life, such as hearing loss or brain-related problems. Two cohort studies from Wales and Thailand both reported high overall survival, but they also documented reactivation or relapse in a notable portion of patients. Another study focused on hearing loss and found it was uncommon but linked to ear lesions and to a higher rate of later CNS-progressive complications. [4] [5] [6]

In a 35-child series from Wales, most skeletal LCH was unifocal and often managed conservatively, while multifocal bone or multisystem cases more often received vinblastine and prednisolone-based chemotherapy. All children were alive at last follow-up, and relapses were reported in 8 patients, with no long-term skeletal complications noted in this cohort. The study also reported that some children were diagnosed based on clinical and imaging findings without biopsy, reflecting real-world variation in how LCH is confirmed. [4]

In a 40-year cohort from Southern Thailand of 68 children treated under national protocols, 5-year overall survival was reported as 91.9% and 5-year event-free survival as 66.1%. The study reported that being diagnosed under age 1 year was an independent predictor of mortality, and that reactivation was more common in multisystem disease. Outcomes improved in the more recent ThaiPOG era compared with earlier eras, suggesting that changes in protocols and supportive care over time may matter. [5]

A Japan-based analysis of 317 children with multisystem or multifocal bone LCH found hearing loss in 2.8% of patients, and it was significantly linked to having ear lesions. Children with hearing loss more often developed CNS-progressive complications, and one child without ear lesions had progressive sensorineural hearing loss attributed to neurodegeneration. This helps connect a specific symptom (hearing loss) with a higher-risk pattern seen later in some patients. [6]

One small, exploratory study in oral and maxillofacial LCH examined immune cells inside lesions and did not find that its patients fit previously described clinical prognostic patterns. It also reported that IL-10 signals from a type of macrophage were inversely related to how actively the LCH cells appeared to be dividing, raising questions about whether parts of the immune response can both restrain and enable disease in different settings. This is hypothesis-generating tissue research rather than a finding that can yet be used to predict an individual's outlook. [7]

For families, this month reinforced two realities at the same time: many children survive and often recover well, but relapse and longer-term complications can still happen and may shape follow-up for years. The hearing-loss study adds a practical insight that when hearing changes occur in childhood LCH, they may be part of a broader pattern that sometimes includes later CNS-related problems, even though hearing loss itself was uncommon. The Thailand and Wales cohorts add context for what outcomes have looked like in different health systems and across different treatment eras, but they cannot predict what will happen for any one child. The tissue-based immune findings are mainly research right now, and their value is in pointing toward questions that future studies can test more directly. [4] [5] [6] [7]

This month included several studies showing how LCH can be mistaken for other conditions based on symptoms or imaging, and how extra testing can clarify what is going on. Imaging-focused work suggested certain MRI patterns may differ between single versus multiple craniofacial bone lesions, while another pediatric series emphasized that clavicle symptoms have many possible causes and LCH is only one of them. Lung-focused pathology research also highlighted that small biopsy samples can look reactive and be misread, and it documented a range of gene changes linked to LCH biology. [8] [9] [10]

For craniofacial bone LCH, a retrospective MRI study of 22 confirmed cases reported that solitary lesions tended to appear in older patients and showed more extensive surrounding bone marrow swelling and surrounding bone enhancement than multiple-lesion cases. The authors suggested these patterns may help distinguish solitary from multiple presentations, which could matter because LCH is managed differently depending on extent. Because MRI protocols varied over many years, these imaging patterns should be seen as helpful clues rather than definitive rules. [8]

For children with non-traumatic clavicle pain or swelling, a small multi-center Italian series found that most cases were chronic nonbacterial osteomyelitis, while 2 of 12 were ultimately diagnosed as LCH. The accompanying literature review also showed a wide mix of causes in reported pediatric clavicle cases, reinforcing that LCH is part of a broad differential diagnosis. The study highlighted that broader imaging, such as whole-body MRI, can reveal multifocal bone involvement in some conditions, which can change how the overall problem is understood. [9]

A registry analysis of 908 primary spine tumors in Japan reported that LCH accounted for 7.0% of cases in this spine-tumor registry. This does not describe the overall frequency of LCH in the population, but it helps show that LCH is a recognizable cause among tumors that present in the spine and may enter orthopedic tumor registries. The study also described how often imaging-based diagnosis and surgery were used across tumor types, giving context for how spine lesions are managed in practice. [11]

In pulmonary LCH, a 13-case clinicopathologic series described typical imaging and tissue marker patterns and reported that some small biopsies were initially misdiagnosed as reactive lesions. Genetic testing in a subset found a range of molecular alterations, including changes in BRAF, MAP2K1, DUSP4, and RRAS, and follow-up was generally favorable in the short term in this small group. This adds to the idea that pulmonary LCH can share a common disease identity while still having varied underlying gene changes. [10]

One additional case report illustrated a diagnostic pitfall during cancer follow-up: new lung nodules in a smoker previously treated for mesothelioma were initially suspected to be metastases but were diagnosed as pulmonary LCH after bronchoscopy sampling. The main lesson from this single case is that LCH can sometimes mimic other serious conditions on scans, especially in the lung. [12]

For patients and caregivers, this group of studies mainly adds clarity about why diagnosing LCH can take time and why the same symptom can have many causes. The MRI and clavicle studies suggest that patterns on imaging and the presence of lesions in more than one place can help doctors sort between LCH and look-alike conditions, but these are not stand-alone tests. The pulmonary pathology study helps explain why some lung biopsies may be misread at first and why molecular testing can sometimes add helpful information about the biology of the disease. These findings matter most for understanding the diagnostic process and for shaping future research, rather than changing treatment decisions by themselves. [8] [9] [10] [11] [12]

This month’s case reports emphasized how widely LCH can present across ages and organs, and how outcomes can be limited when damage is already established or disease is advanced. Several cases involved unusual or easily misinterpreted starting points, such as sudden hearing loss from a temporal bone lesion, oral disease that later became multisystem, and pericardial fluid buildup in an overlap histiocytosis condition. A separate case with a BRAF V600E mutation described partial neurologic improvement after targeted therapy, but with persistent deficits over time, showing the challenges of CNS involvement. [13] [14] [15] [16]

Ear and hearing involvement appeared in two different ways across reports this month. A 24-year-old man had sudden sensorineural hearing loss from LCH localized to the temporal bone, and hearing did not improve after 6 months following biopsy and referral for chemotherapy. This single case adds to the picture that hearing loss can be a presenting symptom, and recovery is not guaranteed once hearing is lost. [13]

Several cases highlighted multisystem disease and overlap syndromes. A 27-year-old man with oral-onset LCH progressed from localized disease to multisystem involvement confirmed by PET/CT, illustrating that LCH can spread beyond the mouth over time in some individuals. A 49-year-old woman was diagnosed with overlap Erdheim-Chester disease and LCH with a BRAF V600E mutation and presented mainly with pericardial effusion, with follow-up described as clinically stable after drainage and supportive care. [14] [15]

CNS-involved histiocytosis was represented by one report of mixed histiocytosis (LCH/ECD) with a BRAF V600E mutation treated with dabrafenib plus trametinib (targeted therapy). Neurological scores and a brainstem lesion on MRI improved after 7 months, but by 21 months the person still had persistent neurological deficits and only partial recovery. This case adds a real-world example that targeted therapy may help some CNS findings, yet recovery can remain incomplete, especially when treatment begins late. [16]

A pediatric case report described a 2-year-old boy with disseminated LCH and central diabetes insipidus, with extensive skin and bone involvement and pituitary stalk thickening on imaging. The report described treatment with prednisone and vinblastine induction followed by maintenance therapy, and it noted that diabetes insipidus was managed with hydration during hospitalization because desmopressin was unavailable. This case mainly illustrates the complexity of multisystem LCH care in some settings rather than providing comparative outcome information. [17]

For patients, these case reports do not tell what is typical, but they expand the map of what LCH can look like and why it can be mistaken for other conditions. They also underline that some symptoms, such as hearing loss or neurologic problems, may not fully reverse even when LCH is later treated, which can affect quality of life. The targeted-therapy and overlap-syndrome cases show that genetic findings like BRAF V600E can be part of the story in some people, but single-patient experiences cannot predict how others will respond. The main value of these reports is awareness and hypothesis-building for future research, not changing care on their own. [13] [14] [15] [16] [17]